Date: 2015-09-29
Type of information: Nomination
Compound:
Company: Enterome Bioscience (France)
Therapeutic area: Autoimmune diseases - Inflammatory diseases - Digestive diseases
Type agreement: nomination
Action mechanism:
Disease:
Details: * On September 29, 2015, Enterome Bioscience, a pioneer in the development of therapeutic solutions (drugs and diagnostics) based on a deep understanding of the gut microbiome, announced that Georges Gemayel PhD has joined the Enterome board as a Non-executive Chairman. He replaces Bernard Gilly, who becomes a Non-executive Director. Dr Gemayel has over 25 years of experience in the pharmaceutical industry, including management and executive positions in the US, Europe and the Middle East. He currently serves on the board of directors of US publicly-traded companies Supernus Pharmaceuticals, Inc., Raptor Pharmaceutical Corp., and Dimension Therapeutics a privately owned company. He is the Chairman of the boards of OxThera AB, and Orphazyme ApS. From 2008 to 2009, Dr Gemayel was President and Chief Executive Officer of Altus Pharmaceuticals Inc., a publicly-traded pharmaceutical company. From 2003 to 2008, he was Executive Vice President at Genzyme Corporation where he was responsible for the company\'s global therapeutics, transplant, renal and biosurgery businesses. From 1988 to 2003, he held progressively senior roles at Hoffmann La-Roche and Roche Labs, most recently as Vice President, National Specialty Care, responsible for its US business for dermatology, oncology, transplantation, hepatitis and HIV.
Financial terms:
Latest news:
